This finding sheds light on the potential effect of SGLT1 and SGLT2 inhibition on protecting skeletal muscle cells, offering a novel approach to address ageing and degeneration in skeletal muscle, such as frailty and sarcopenia. This evidence concerns the gene SLC5A2 and sarcopenia.